VRDN-008 demonstrated an extended half-life of 15–18 days, up to 6x longer than the first-generation Fc fragments -

- VRDN-008 demonstrated a safety profile that spared albumin and LDL and was generally well tolerated -

- Viridian plans to initiate at least one pivotal clinical trial in 2027, starting with myasthenia gravis (MG) in mid-2027, pending regulatory feedback -

- Planned MG placebo-controlled multi-arm trial design with Q4W and Q8W dosing supports direct-to-registrational path -

- With the potential to deliver transformative patient impact across autoantibody-mediated autoimmune diseases, Viridian plans to develop VRDN-008 broadly in multiple of these autoimmune diseases -

- Viridian to host investor conference call and webcast today at 8:00 am ET

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.